TWI611021B - Ｈｓｐ４７表現之調節 - Google Patents

Info

Publication number

TWI611021B

TWI611021B TW105114241A TW105114241A TWI611021B TW I611021 B TWI611021 B TW I611021B TW 105114241 A TW105114241 A TW 105114241A TW 105114241 A TW105114241 A TW 105114241A TW I611021 B TWI611021 B TW I611021B

Authority

TW

Taiwan

Prior art keywords

nucleic acid

nucleotide

nucleotides

modified

seq

Prior art date

2009-12-09

Links

• Espacenet
• Global Dossier
• Discuss

• 230000014509 gene expression Effects 0.000 title description 39
• 150000007523 nucleic acids Chemical class 0.000 claims abstract description 487
• 102000039446 nucleic acids Human genes 0.000 claims abstract description 470
• 108020004707 nucleic acids Proteins 0.000 claims abstract description 470
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 55
• 239000000203 mixture Substances 0.000 claims abstract description 53
• 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 48
• 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 28
• 108010055039 HSP47 Heat-Shock Proteins Proteins 0.000 claims abstract description 23
• 201000002793 renal fibrosis Diseases 0.000 claims abstract description 15
• 206010034665 Peritoneal fibrosis Diseases 0.000 claims abstract description 11
• 102000001214 HSP47 Heat-Shock Proteins Human genes 0.000 claims abstract 7
• 125000003729 nucleotide group Chemical group 0.000 claims description 631
• 239000002773 nucleotide Substances 0.000 claims description 568
• 230000000692 anti-sense effect Effects 0.000 claims description 361
• 125000002652 ribonucleotide group Chemical group 0.000 claims description 221
• 108091081021 Sense strand Proteins 0.000 claims description 194
• 239000002336 ribonucleotide Substances 0.000 claims description 194
• 108091028664 Ribonucleotide Proteins 0.000 claims description 192
• 208000035657 Abasia Diseases 0.000 claims description 91
• 230000004048 modification Effects 0.000 claims description 91
• 238000012986 modification Methods 0.000 claims description 91
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 86
• 230000002441 reversible effect Effects 0.000 claims description 86
• 239000005547 deoxyribonucleotide Substances 0.000 claims description 81
• 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 79
• 235000000346 sugar Nutrition 0.000 claims description 66
• -1 6-azouracil Chemical compound 0.000 claims description 65
• 206010016654 Fibrosis Diseases 0.000 claims description 62
• 230000000295 complement effect Effects 0.000 claims description 61
• 210000001519 tissue Anatomy 0.000 claims description 52
• 230000004761 fibrosis Effects 0.000 claims description 49
• 201000010099 disease Diseases 0.000 claims description 47
• 125000000217 alkyl group Chemical group 0.000 claims description 45
• 229910052757 nitrogen Inorganic materials 0.000 claims description 41
• 239000002253 acid Substances 0.000 claims description 39
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 36
• 229910019142 PO4 Inorganic materials 0.000 claims description 34
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 34
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 33
• 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 32
• 229960005305 adenosine Drugs 0.000 claims description 32
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 32
• 239000010452 phosphate Substances 0.000 claims description 32
• 235000021317 phosphate Nutrition 0.000 claims description 30
• 108020004999 messenger RNA Proteins 0.000 claims description 29
• 108091034117 Oligonucleotide Proteins 0.000 claims description 28
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 27
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 23
• 108020004414 DNA Proteins 0.000 claims description 21
• ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 20
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 18
• 229940104302 cytosine Drugs 0.000 claims description 18
• 239000002777 nucleoside Substances 0.000 claims description 15
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 14
• 230000007882 cirrhosis Effects 0.000 claims description 13
• 230000003176 fibrotic effect Effects 0.000 claims description 13
• 210000003734 kidney Anatomy 0.000 claims description 12
• 210000003491 skin Anatomy 0.000 claims description 12
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
• 229930024421 Adenine Natural products 0.000 claims description 10
• KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical compound O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 claims description 10
• 208000010412 Glaucoma Diseases 0.000 claims description 10
• 229960000643 adenine Drugs 0.000 claims description 10
• 125000004122 cyclic group Chemical group 0.000 claims description 10
• 210000004185 liver Anatomy 0.000 claims description 10
• 230000036573 scar formation Effects 0.000 claims description 10
• 229940035893 uracil Drugs 0.000 claims description 10
• 206010039710 Scleroderma Diseases 0.000 claims description 9
• 210000001508 eye Anatomy 0.000 claims description 9
• 125000000548 ribosyl group Chemical class C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 9
• 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 8
• 206010038934 Retinopathy proliferative Diseases 0.000 claims description 8
• 230000002159 abnormal effect Effects 0.000 claims description 8
• 150000001412 amines Chemical class 0.000 claims description 8
• 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 8
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
• 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 8
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 7
• MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 7
• NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 7
• 206010067125 Liver injury Diseases 0.000 claims description 7
• 229940029575 guanosine Drugs 0.000 claims description 7
• 150000002430 hydrocarbons Chemical class 0.000 claims description 7
• 210000004072 lung Anatomy 0.000 claims description 7
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 7
• 239000002342 ribonucleoside Substances 0.000 claims description 7
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 6
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 6
• 231100000012 chronic liver injury Toxicity 0.000 claims description 6
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 6
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 6
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
• 229940113082 thymine Drugs 0.000 claims description 6
• 125000002015 acyclic group Chemical group 0.000 claims description 5
• 230000009787 cardiac fibrosis Effects 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 210000002216 heart Anatomy 0.000 claims description 5
• 206010028537 myelofibrosis Diseases 0.000 claims description 5
• 150000004713 phosphodiesters Chemical group 0.000 claims description 5
• 239000005451 thionucleotide Substances 0.000 claims description 5
• UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 claims description 4
• 206010000050 Abdominal adhesions Diseases 0.000 claims description 4
• 239000004215 Carbon black (E152) Substances 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• 208000034189 Sclerosis Diseases 0.000 claims description 4
• 230000035557 fibrillogenesis Effects 0.000 claims description 4
• 238000001914 filtration Methods 0.000 claims description 4
• 229930195733 hydrocarbon Natural products 0.000 claims description 4
• 208000010125 myocardial infarction Diseases 0.000 claims description 4
• 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 229910052698 phosphorus Inorganic materials 0.000 claims description 4
• 239000011574 phosphorus Substances 0.000 claims description 4
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 claims description 3
• MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims description 3
• QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical compound COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 claims description 3
• 206010010356 Congenital anomaly Diseases 0.000 claims description 3
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 3
• 125000001475 halogen functional group Chemical group 0.000 claims description 3
• 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 3
• 210000001525 retina Anatomy 0.000 claims description 3
• DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 claims description 3
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
• 229940075420 xanthine Drugs 0.000 claims description 3
• FGODUFHTWYYOOB-UHFFFAOYSA-N 1,3-diaminopropan-2-yl dihydrogen phosphate Chemical class NCC(CN)OP(O)(O)=O FGODUFHTWYYOOB-UHFFFAOYSA-N 0.000 claims description 2
• MPCAJMNYNOGXPB-UHFFFAOYSA-N 1,5-anhydrohexitol Chemical class OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 claims description 2
• NXEGRTVWWNBQLW-UHFFFAOYSA-N 12-aminododecyl dihydrogen phosphate Chemical compound NCCCCCCCCCCCCOP(O)(O)=O NXEGRTVWWNBQLW-UHFFFAOYSA-N 0.000 claims description 2
• HYCSHFLKPSMPGO-UHFFFAOYSA-N 3-hydroxypropyl dihydrogen phosphate Chemical compound OCCCOP(O)(O)=O HYCSHFLKPSMPGO-UHFFFAOYSA-N 0.000 claims description 2
• LZINOQJQXIEBNN-UHFFFAOYSA-N 4-hydroxybutyl dihydrogen phosphate Chemical compound OCCCCOP(O)(O)=O LZINOQJQXIEBNN-UHFFFAOYSA-N 0.000 claims description 2
• XYVLZAYJHCECPN-UHFFFAOYSA-N 6-aminohexyl phosphate Chemical compound NCCCCCCOP(O)(O)=O XYVLZAYJHCECPN-UHFFFAOYSA-N 0.000 claims description 2
• OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 claims description 2
• 201000001320 Atherosclerosis Diseases 0.000 claims description 2
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
• 208000006069 Corneal Opacity Diseases 0.000 claims description 2
• 206010031023 Oral submucosal fibrosis Diseases 0.000 claims description 2
• 208000031472 Retinal fibrosis Diseases 0.000 claims description 2
• 210000001185 bone marrow Anatomy 0.000 claims description 2
• 125000002837 carbocyclic group Chemical group 0.000 claims description 2
• 231100000269 corneal opacity Toxicity 0.000 claims description 2
• 206010020718 hyperplasia Diseases 0.000 claims description 2
• 238000005304 joining Methods 0.000 claims description 2
• 230000003211 malignant effect Effects 0.000 claims description 2
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
• UFEJKYYYVXYMMS-UHFFFAOYSA-N methylcarbamic acid Chemical group CNC(O)=O UFEJKYYYVXYMMS-UHFFFAOYSA-N 0.000 claims description 2
• 230000002988 nephrogenic effect Effects 0.000 claims description 2
• 208000005207 oral submucous fibrosis Diseases 0.000 claims description 2
• 210000004303 peritoneum Anatomy 0.000 claims description 2
• 230000009885 systemic effect Effects 0.000 claims description 2
• 210000001260 vocal cord Anatomy 0.000 claims 2
• 206010051113 Arterial restenosis Diseases 0.000 claims 1
• 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
• 206010072877 Intestinal fibrosis Diseases 0.000 claims 1
• 206010067776 Ocular pemphigoid Diseases 0.000 claims 1
• QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
• 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
• 206010042953 Systemic sclerosis Diseases 0.000 claims 1
• 201000010002 cicatricial pemphigoid Diseases 0.000 claims 1
• 230000002518 glial effect Effects 0.000 claims 1
• 125000003147 glycosyl group Chemical group 0.000 claims 1
• 208000024908 graft versus host disease Diseases 0.000 claims 1
• 210000000936 intestine Anatomy 0.000 claims 1
• 210000004877 mucosa Anatomy 0.000 claims 1
• 210000000651 myofibroblast Anatomy 0.000 claims 1
• 210000000496 pancreas Anatomy 0.000 claims 1
• 208000017520 skin disease Diseases 0.000 claims 1
• 230000002792 vascular Effects 0.000 claims 1
• 210000005166 vasculature Anatomy 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 abstract description 84
• 238000000034 method Methods 0.000 abstract description 71
• 239000004055 small Interfering RNA Substances 0.000 abstract description 53
• 108020004459 Small interfering RNA Proteins 0.000 abstract description 43
• 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 37
• 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract description 37
• 230000002452 interceptive effect Effects 0.000 abstract description 16
• 108700011259 MicroRNAs Proteins 0.000 abstract description 12
• 239000002679 microRNA Substances 0.000 abstract description 12
• 108091027967 Small hairpin RNA Proteins 0.000 abstract description 11
• 208000035475 disorder Diseases 0.000 abstract description 8
• 230000001105 regulatory effect Effects 0.000 abstract description 5
• 239000002585 base Substances 0.000 description 87
• 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 78
• 230000009368 gene silencing by RNA Effects 0.000 description 78
• 102100023387 Endoribonuclease Dicer Human genes 0.000 description 77
• 210000004027 cell Anatomy 0.000 description 48
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 46
• 239000000758 substrate Substances 0.000 description 45
• 108091030071 RNAI Proteins 0.000 description 44
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 33
• 231100000241 scar Toxicity 0.000 description 33
• 208000020832 chronic kidney disease Diseases 0.000 description 32
• 150000003212 purines Chemical group 0.000 description 32
• 208000006111 contracture Diseases 0.000 description 27
• 239000002213 purine nucleotide Substances 0.000 description 26
• 230000000694 effects Effects 0.000 description 25
• 239000003607 modifier Substances 0.000 description 25
• 150000003230 pyrimidines Chemical class 0.000 description 25
• 239000003814 drug Substances 0.000 description 23
• 238000011282 treatment Methods 0.000 description 23
• 108091028043 Nucleic acid sequence Proteins 0.000 description 22
• 102100027287 Serpin H1 Human genes 0.000 description 22
• 235000018102 proteins Nutrition 0.000 description 19
• 102000004169 proteins and genes Human genes 0.000 description 19
• 206010062575 Muscle contracture Diseases 0.000 description 18
• 102000040430 polynucleotide Human genes 0.000 description 18
• 108091033319 polynucleotide Proteins 0.000 description 18
• 239000002157 polynucleotide Substances 0.000 description 18
• 238000012545 processing Methods 0.000 description 17
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 16
• 239000002299 complementary DNA Substances 0.000 description 16
• 238000009472 formulation Methods 0.000 description 16
• 238000001356 surgical procedure Methods 0.000 description 16
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 16
• 229940045145 uridine Drugs 0.000 description 16
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 16
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 15
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 14
• 150000001875 compounds Chemical class 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• MHZDONKZSXBOGL-UHFFFAOYSA-N propyl dihydrogen phosphate Chemical compound CCCOP(O)(O)=O MHZDONKZSXBOGL-UHFFFAOYSA-N 0.000 description 14
• 239000002719 pyrimidine nucleotide Substances 0.000 description 14
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 13
• 241000700159 Rattus Species 0.000 description 12
• 239000000443 aerosol Substances 0.000 description 12
• 239000002502 liposome Substances 0.000 description 12
• 102000008186 Collagen Human genes 0.000 description 11
• 108010035532 Collagen Proteins 0.000 description 11
• 238000007385 chemical modification Methods 0.000 description 11
• 229920001436 collagen Polymers 0.000 description 11
• 239000005090 green fluorescent protein Substances 0.000 description 11
• 210000000056 organ Anatomy 0.000 description 11
• JTEGQNOMFQHVDC-RQJHMYQMSA-N 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1 JTEGQNOMFQHVDC-RQJHMYQMSA-N 0.000 description 10
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
• 125000003545 alkoxy group Chemical group 0.000 description 10
• 230000027455 binding Effects 0.000 description 10
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 10
• 125000003835 nucleoside group Chemical group 0.000 description 10
• 230000037390 scarring Effects 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 9
• 208000032544 Cicatrix Diseases 0.000 description 9
• 208000029523 Interstitial Lung disease Diseases 0.000 description 9
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
• 230000006378 damage Effects 0.000 description 9
• MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 230000037387 scars Effects 0.000 description 9
• 208000002260 Keloid Diseases 0.000 description 8
• 229920002873 Polyethylenimine Polymers 0.000 description 8
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 8
• 210000003169 central nervous system Anatomy 0.000 description 8
• 238000000502 dialysis Methods 0.000 description 8
• 210000001117 keloid Anatomy 0.000 description 8
• 208000017169 kidney disease Diseases 0.000 description 8
• 210000000885 nephron Anatomy 0.000 description 8
• 210000004940 nucleus Anatomy 0.000 description 8
• 101000836383 Homo sapiens Serpin H1 Proteins 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• ZEXSWWSPNTYEJC-UHFFFAOYSA-N dihydroxy-propoxy-sulfanylidene-$l^{5}-phosphane Chemical compound CCCOP(O)(O)=S ZEXSWWSPNTYEJC-UHFFFAOYSA-N 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 239000002245 particle Substances 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 108090000765 processed proteins & peptides Proteins 0.000 description 7
• 108091026890 Coding region Proteins 0.000 description 6
• 108010022452 Collagen Type I Proteins 0.000 description 6
• 102000012422 Collagen Type I Human genes 0.000 description 6
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 6
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 6
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
• 201000000523 end stage renal failure Diseases 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 238000010348 incorporation Methods 0.000 description 6
• 125000005647 linker group Chemical group 0.000 description 6
• 102000004196 processed proteins & peptides Human genes 0.000 description 6
• 238000007634 remodeling Methods 0.000 description 6
• 150000003290 ribose derivatives Chemical class 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 5
• YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 5
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
• 206010038848 Retinal detachment Diseases 0.000 description 5
• 239000000074 antisense oligonucleotide Substances 0.000 description 5
• 238000012230 antisense oligonucleotides Methods 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 229940125904 compound 1 Drugs 0.000 description 5
• 229940125782 compound 2 Drugs 0.000 description 5
• 229940126214 compound 3 Drugs 0.000 description 5
• 229940125898 compound 5 Drugs 0.000 description 5
• 239000005549 deoxyribonucleoside Substances 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 208000033679 diabetic kidney disease Diseases 0.000 description 5
• 210000002950 fibroblast Anatomy 0.000 description 5
• 239000001257 hydrogen Substances 0.000 description 5
• 229910052739 hydrogen Inorganic materials 0.000 description 5
• 239000007943 implant Substances 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 230000003902 lesion Effects 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 229920000166 polytrimethylene carbonate Polymers 0.000 description 5
• 230000032361 posttranscriptional gene silencing Effects 0.000 description 5
• 230000005855 radiation Effects 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 230000004264 retinal detachment Effects 0.000 description 5
• 150000008163 sugars Chemical class 0.000 description 5
• 229910052717 sulfur Inorganic materials 0.000 description 5
• OFEZSBMBBKLLBJ-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 4
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 4
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• 206010023330 Keloid scar Diseases 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 108091093037 Peptide nucleic acid Proteins 0.000 description 4
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
• 108010001267 Protein Subunits Proteins 0.000 description 4
• 101000836384 Rattus norvegicus Serpin H1 Proteins 0.000 description 4
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 239000002537 cosmetic Substances 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 210000002744 extracellular matrix Anatomy 0.000 description 4
• 206010061989 glomerulosclerosis Diseases 0.000 description 4
• 229910052736 halogen Inorganic materials 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 238000012423 maintenance Methods 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 210000001428 peripheral nervous system Anatomy 0.000 description 4
• 230000010363 phase shift Effects 0.000 description 4
• 239000001294 propane Substances 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 208000011580 syndromic disease Diseases 0.000 description 4
• 229940104230 thymidine Drugs 0.000 description 4
• 238000002054 transplantation Methods 0.000 description 4
• HWRFTOWHSBECMR-UHFFFAOYSA-N 6-n-[(4-aminophenyl)methyl]-2-n-[[3-(trifluoromethyl)phenyl]methyl]-7h-purine-2,6-diamine Chemical group C1=CC(N)=CC=C1CNC1=NC(NCC=2C=C(C=CC=2)C(F)(F)F)=NC2=C1NC=N2 HWRFTOWHSBECMR-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• 108091023037 Aptamer Proteins 0.000 description 3
• 206010061876 Obstruction Diseases 0.000 description 3
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
• 206010061481 Renal injury Diseases 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 206010064930 age-related macular degeneration Diseases 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 125000002877 alkyl aryl group Chemical group 0.000 description 3
• 125000000304 alkynyl group Chemical group 0.000 description 3
• 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 3
• 150000001413 amino acids Chemical group 0.000 description 3
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 150000007942 carboxylates Chemical class 0.000 description 3
• 210000004413 cardiac myocyte Anatomy 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 3
• 229940109239 creatinine Drugs 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 210000000805 cytoplasm Anatomy 0.000 description 3
• 238000005034 decoration Methods 0.000 description 3
• 230000008021 deposition Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 210000000744 eyelid Anatomy 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 238000001631 haemodialysis Methods 0.000 description 3
• 150000002367 halogens Chemical class 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 230000000322 hemodialysis Effects 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 231100000283 hepatitis Toxicity 0.000 description 3
• 125000001072 heteroaryl group Chemical group 0.000 description 3
• 125000000623 heterocyclic group Chemical group 0.000 description 3
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 102000048954 human SERPINH1 Human genes 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 208000003476 primary myelofibrosis Diseases 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 150000008223 ribosides Chemical class 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 239000003001 serine protease inhibitor Substances 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 125000001424 substituent group Chemical group 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 239000013589 supplement Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 238000011191 terminal modification Methods 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 230000029812 viral genome replication Effects 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
• ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• 206010006448 Bronchiolitis Diseases 0.000 description 2
• YXNNSWYDFRWCBQ-UHFFFAOYSA-N C(C)(=O)O.P(O)(O)=O Chemical compound C(C)(=O)O.P(O)(O)=O YXNNSWYDFRWCBQ-UHFFFAOYSA-N 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• 108010077544 Chromatin Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
• 208000001708 Dupuytren contracture Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 2
• 208000003084 Graves Ophthalmopathy Diseases 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 208000018565 Hemochromatosis Diseases 0.000 description 2
• 208000005176 Hepatitis C Diseases 0.000 description 2
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 206010020880 Hypertrophy Diseases 0.000 description 2
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
• 206010021263 IgA nephropathy Diseases 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• 206010023421 Kidney fibrosis Diseases 0.000 description 2
• 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 206010028594 Myocardial fibrosis Diseases 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 206010034277 Pemphigoid Diseases 0.000 description 2
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• 102000002067 Protein Subunits Human genes 0.000 description 2
• 229930185560 Pseudouridine Natural products 0.000 description 2
• PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
• 201000002154 Pterygium Diseases 0.000 description 2
• 238000011529 RT qPCR Methods 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
• 102000008847 Serpin Human genes 0.000 description 2
• 108050000761 Serpin Proteins 0.000 description 2
• 208000028990 Skin injury Diseases 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000018839 Wilson disease Diseases 0.000 description 2
• 206010052428 Wound Diseases 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 2
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
• 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
• 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 2
• 125000004414 alkyl thio group Chemical group 0.000 description 2
• 125000003368 amide group Chemical group 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 125000005122 aminoalkylamino group Chemical group 0.000 description 2
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
• 125000003710 aryl alkyl group Chemical group 0.000 description 2
• 125000005129 aryl carbonyl group Chemical group 0.000 description 2
• 125000005199 aryl carbonyloxy group Chemical group 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 125000005110 aryl thio group Chemical group 0.000 description 2
• 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 2
• 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 description 2
• WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 244000309464 bull Species 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 210000001054 cardiac fibroblast Anatomy 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 239000000460 chlorine Substances 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 210000003483 chromatin Anatomy 0.000 description 2
• 108010038679 colligin Proteins 0.000 description 2
• 125000004093 cyano group Chemical group *C#N 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000001066 destructive effect Effects 0.000 description 2
• 125000005265 dialkylamine group Chemical group 0.000 description 2
• 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 2
• 125000005266 diarylamine group Chemical group 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
• 230000035876 healing Effects 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 230000000642 iatrogenic effect Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 208000037806 kidney injury Diseases 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 108091008104 nucleic acid aptamers Proteins 0.000 description 2
• 210000004279 orbit Anatomy 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 230000010412 perfusion Effects 0.000 description 2
• 210000002706 plastid Anatomy 0.000 description 2
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
• 229920000768 polyamine Polymers 0.000 description 2
• 229920000573 polyethylene Polymers 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
• 229920002477 rna polymer Polymers 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 229940063675 spermine Drugs 0.000 description 2
• 210000004500 stellate cell Anatomy 0.000 description 2
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 150000007970 thio esters Chemical class 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 2
• 238000000108 ultra-filtration Methods 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• YROJWWHYHBKDPB-VEGRVEBRSA-N (2r,3r,4r)-2,3,4,5-tetrahydroxypentanal;trihydroxy(sulfanylidene)-$l^{5}-phosphane Chemical compound OP(O)(O)=S.OC[C@@H](O)[C@@H](O)[C@@H](O)C=O YROJWWHYHBKDPB-VEGRVEBRSA-N 0.000 description 1
• BDPULNJEMMNNMI-BFJMCJFZSA-N (2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-2-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(C2[C@@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H]1O BDPULNJEMMNNMI-BFJMCJFZSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• HCITUYXHCZGFEO-UHFFFAOYSA-N 1,3,5-triazine-2,4,6-triamine Chemical compound NC1=NC(N)=NC(N)=N1.N=C1NC(=N)NC(=N)N1 HCITUYXHCZGFEO-UHFFFAOYSA-N 0.000 description 1
• XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• QMQZIXCNLUPEIN-UHFFFAOYSA-N 1h-imidazole-2-carbonitrile Chemical compound N#CC1=NC=CN1 QMQZIXCNLUPEIN-UHFFFAOYSA-N 0.000 description 1
• BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
• IZGFERLHOCMZQF-UHFFFAOYSA-N 2-(10h-phenoxazin-1-yloxy)ethanamine Chemical compound O1C2=CC=CC=C2NC2=C1C=CC=C2OCCN IZGFERLHOCMZQF-UHFFFAOYSA-N 0.000 description 1
• PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
• 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
• 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
• YQSPOXMPYQYCSI-UHFFFAOYSA-N 2-methoxy-1h-imidazole Chemical compound COC1=NC=CN1 YQSPOXMPYQYCSI-UHFFFAOYSA-N 0.000 description 1
• KMEBCRWKZZSRRT-UHFFFAOYSA-N 2-methyl-7h-purine Chemical class CC1=NC=C2NC=NC2=N1 KMEBCRWKZZSRRT-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• LNQVTSROQXJCDD-KQYNXXCUSA-N 3'-AMP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O LNQVTSROQXJCDD-KQYNXXCUSA-N 0.000 description 1
• KUQZVISZELWDNZ-UHFFFAOYSA-N 3-aminopropyl dihydrogen phosphate Chemical compound NCCCOP(O)(O)=O KUQZVISZELWDNZ-UHFFFAOYSA-N 0.000 description 1
• LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
• KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
• SXQMWXNOYLLRBY-UHFFFAOYSA-N 6-(methylamino)purin-8-one Chemical compound CNC1=NC=NC2=NC(=O)N=C12 SXQMWXNOYLLRBY-UHFFFAOYSA-N 0.000 description 1
• QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 208000012260 Accidental injury Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
• 208000024985 Alport syndrome Diseases 0.000 description 1
• 206010003658 Atrial Fibrillation Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010006500 Brucellosis Diseases 0.000 description 1
• 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
• 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
• 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
• 102100021868 Calnexin Human genes 0.000 description 1
• 108010056891 Calnexin Proteins 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
• 208000009043 Chemical Burns Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
• 206010009137 Chronic sinusitis Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 208000028006 Corneal injury Diseases 0.000 description 1
• 206010063075 Cryptogenic cirrhosis Diseases 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 201000003808 Cystic echinococcosis Diseases 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
• 206010061619 Deformity Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 208000003164 Diplopia Diseases 0.000 description 1
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
• 206010013774 Dry eye Diseases 0.000 description 1
• 206010014096 Echinococciasis Diseases 0.000 description 1
• 208000009366 Echinococcosis Diseases 0.000 description 1
• 102000016942 Elastin Human genes 0.000 description 1
• 108010014258 Elastin Proteins 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 206010053177 Epidermolysis Diseases 0.000 description 1
• 206010015124 Ergot poisoning Diseases 0.000 description 1
• 244000070010 Erythrina variegata Species 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 101710089384 Extracellular protease Proteins 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
• 208000015872 Gaucher disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 101710142014 Gene 46 protein Proteins 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
• 206010019668 Hepatic fibrosis Diseases 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 208000031814 IgA Vasculitis Diseases 0.000 description 1
• 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• 206010022530 Intercapillary glomerulosclerosis Diseases 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 208000032984 Intraoperative Complications Diseases 0.000 description 1
• 206010065973 Iron Overload Diseases 0.000 description 1
• 229930194542 Keto Natural products 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 208000016272 Ledderhose disease Diseases 0.000 description 1
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 206010025219 Lymphangioma Diseases 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 229920000877 Melamine resin Polymers 0.000 description 1
• 102000005431 Molecular Chaperones Human genes 0.000 description 1
• 108010006519 Molecular Chaperones Proteins 0.000 description 1
• MRWXACSTFXYYMV-UHFFFAOYSA-N Nebularine Natural products OC1C(O)C(CO)OC1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-UHFFFAOYSA-N 0.000 description 1
• 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 1
• 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 1
• 208000001738 Nervous System Trauma Diseases 0.000 description 1
• JZTPOMIFAFKKSK-UHFFFAOYSA-N O-phosphonohydroxylamine Chemical compound NOP(O)(O)=O JZTPOMIFAFKKSK-UHFFFAOYSA-N 0.000 description 1
• OSRWYQUSDMUYBS-UHFFFAOYSA-N OBO.OP(O)(O)=O Chemical compound OBO.OP(O)(O)=O OSRWYQUSDMUYBS-UHFFFAOYSA-N 0.000 description 1
• HCJWCUDNVVDOMX-UHFFFAOYSA-N OP(O)(O)=O.[SeH2] Chemical compound OP(O)(O)=O.[SeH2] HCJWCUDNVVDOMX-UHFFFAOYSA-N 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 206010053159 Organ failure Diseases 0.000 description 1
• 206010033649 Pancreatitis chronic Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 208000004362 Penile Induration Diseases 0.000 description 1
• 229940122344 Peptidase inhibitor Drugs 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 208000020758 Peyronie disease Diseases 0.000 description 1
• 201000003687 Plantar fascial fibromatosis Diseases 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 229920000148 Polycarbophil calcium Polymers 0.000 description 1
• 206010036346 Posterior capsule opacification Diseases 0.000 description 1
• 201000007902 Primary cutaneous amyloidosis Diseases 0.000 description 1
• 229910052774 Proactinium Inorganic materials 0.000 description 1
• 108010050808 Procollagen Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 230000007022 RNA scission Effects 0.000 description 1
• 206010037765 Radiation pneumonitis Diseases 0.000 description 1
• 206010063562 Radiation skin injury Diseases 0.000 description 1
• 208000035977 Rare disease Diseases 0.000 description 1
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
• 206010062104 Renal mass Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 208000002367 Retinal Perforations Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038897 Retinal tear Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 108010057163 Ribonuclease III Proteins 0.000 description 1
• 102000003661 Ribonuclease III Human genes 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 208000007893 Salpingitis Diseases 0.000 description 1
• 229940122055 Serine protease inhibitor Drugs 0.000 description 1
• 101710102218 Serine protease inhibitor Proteins 0.000 description 1
• BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• 206010050207 Skin fibrosis Diseases 0.000 description 1
• 108091060271 Small temporal RNA Proteins 0.000 description 1
• 239000004147 Sorbitan trioleate Substances 0.000 description 1
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• 208000004350 Strabismus Diseases 0.000 description 1
• 241000272534 Struthio camelus Species 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 101800001271 Surface protein Proteins 0.000 description 1
• 208000021945 Tendon injury Diseases 0.000 description 1
• 206010053615 Thermal burn Diseases 0.000 description 1
• 101800000385 Transmembrane protein Proteins 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• 206010064996 Ulcerative keratitis Diseases 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 201000004525 Zellweger Syndrome Diseases 0.000 description 1
• 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
• SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
• 239000003377 acid catalyst Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 230000009692 acute damage Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000004479 aerosol dispenser Substances 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• PYMYPHUHKUWMLA-MROZADKFSA-N aldehydo-L-ribose Chemical compound OC[C@H](O)[C@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-MROZADKFSA-N 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• VFTOLAKHPLTCIF-UHFFFAOYSA-N aminoazanium;dihydrogen phosphate Chemical compound NN.OP(O)(O)=O VFTOLAKHPLTCIF-UHFFFAOYSA-N 0.000 description 1
• JUMVTGDFMDRYKB-UHFFFAOYSA-N aminooxyphosphonamidic acid Chemical compound NOP(N)(O)=O JUMVTGDFMDRYKB-UHFFFAOYSA-N 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000003367 anti-collagen effect Effects 0.000 description 1
• 230000000417 anti-transforming effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 150000008209 arabinosides Chemical class 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 125000005264 aryl amine group Chemical group 0.000 description 1
• 125000005418 aryl aryl group Chemical group 0.000 description 1
• 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 239000005441 aurora Substances 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 201000005271 biliary atresia Diseases 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• YZYDPPZYDIRSJT-UHFFFAOYSA-K boron phosphate Chemical compound [B+3].[O-]P([O-])([O-])=O YZYDPPZYDIRSJT-UHFFFAOYSA-K 0.000 description 1
• 229910000149 boron phosphate Inorganic materials 0.000 description 1
• 230000031709 bromination Effects 0.000 description 1
• 238000005893 bromination reaction Methods 0.000 description 1
• 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 210000005252 bulbus oculi Anatomy 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 210000001736 capillary Anatomy 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical group [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 150000001733 carboxylic acid esters Chemical class 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000002032 cellular defenses Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000017760 chronic graft versus host disease Diseases 0.000 description 1
• 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
• 230000037319 collagen production Effects 0.000 description 1
• 208000008609 collagenous colitis Diseases 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 239000002872 contrast media Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 201000007717 corneal ulcer Diseases 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
• 108091092330 cytoplasmic RNA Proteins 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 238000006392 deoxygenation reaction Methods 0.000 description 1
• 210000004207 dermis Anatomy 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 102000010982 eIF-2 Kinase Human genes 0.000 description 1
• 108010037623 eIF-2 Kinase Proteins 0.000 description 1
• 229920002549 elastin Polymers 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 239000003344 environmental pollutant Substances 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 208000003816 familial cirrhosis Diseases 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 206010016629 fibroma Diseases 0.000 description 1
• 206010049444 fibromatosis Diseases 0.000 description 1
• 239000002657 fibrous material Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
• 210000002683 foot Anatomy 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 201000005917 gastric ulcer Diseases 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000030279 gene silencing Effects 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 210000005086 glomerual capillary Anatomy 0.000 description 1
• 230000024924 glomerular filtration Effects 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 230000003370 grooming effect Effects 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 231100000753 hepatic injury Toxicity 0.000 description 1
• 210000004024 hepatic stellate cell Anatomy 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 208000003215 hereditary nephritis Diseases 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
• 150000002402 hexoses Chemical class 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 201000005991 hyperphosphatemia Diseases 0.000 description 1
• 230000001631 hypertensive effect Effects 0.000 description 1
• 208000015210 hypertensive heart disease Diseases 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 230000010468 interferon response Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 210000004561 lacrimal apparatus Anatomy 0.000 description 1
• 238000013532 laser treatment Methods 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 238000012045 magnetic resonance elastography Methods 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
• 150000007974 melamines Chemical class 0.000 description 1
• 210000001872 metatarsal bone Anatomy 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000003595 mist Substances 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 208000037891 myocardial injury Diseases 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 208000001491 myopia Diseases 0.000 description 1
• 230000004379 myopia Effects 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 231100000637 nephrotoxin Toxicity 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000009437 off-target effect Effects 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 210000002747 omentum Anatomy 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 230000000858 peroxisomal effect Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
• 208000009975 plantar fibromatosis Diseases 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 206010035653 pneumoconiosis Diseases 0.000 description 1
• 229950005134 polycarbophil Drugs 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 229920000570 polyether Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 208000008881 preterm premature rupture of the membranes Diseases 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 201000001474 proteinuria Diseases 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 239000002212 purine nucleoside Substances 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 208000014733 refractive error Diseases 0.000 description 1
• 230000008085 renal dysfunction Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 150000004492 retinoid derivatives Chemical class 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 230000000630 rising effect Effects 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229910000077 silane Inorganic materials 0.000 description 1
• 239000002924 silencing RNA Substances 0.000 description 1
• 230000037380 skin damage Effects 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 235000019337 sorbitan trioleate Nutrition 0.000 description 1
• 229960000391 sorbitan trioleate Drugs 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000005415 substituted alkoxy group Chemical group 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 230000036575 thermal burns Effects 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 206010044325 trachoma Diseases 0.000 description 1
• 229940072041 transforming growth factor beta 2 Drugs 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
• 150000005691 triesters Chemical class 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 201000011296 tyrosinemia Diseases 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 150000002266 vitamin A derivatives Chemical class 0.000 description 1
• 239000000341 volatile oil Substances 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1